Vallon Pharmaceuticals (NASDAQ: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine.
U.S. Legal Council
Thompson Hine LLP
335 Madison Ave, 12th Floor
New York, NY 10017
111 Wood Ave S.
Iselin, NJ 08830
Frequently Asked Questions
How is Vallon stock traded?
Vallon stock is traded on NASDAQ under the ticker symbol VLON
Can I buy stock directly from Vallon?
No, you will need to contact a licensed stockbroker or use an online trading account
How do I get my purchased shares?
What is Vallon’s CUSIP number?
CUSIP # 92023M101
What is Vallon’s industry classification?
Sector: Pharmaceutical Preparations
Where is Vallon’s corporate headquarters?
100 N. 18th Street, Suite 300, Philadelphia, PA 19103
When was Vallon incorporated?
Vallon was incorporated in the state of Delaware on January 11, 2018 and completed its organization, formation, and initial capitalization activities effective as of June 7, 2018
When is Vallon’s fiscal year end?
Who are Vallon’s independent auditors?
Who is Vallon’s outside legal counsel?
Thompson Hine LLP